Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Spectral domain optical coherence tomography in patients with sickle cell disease
source: The British Journal of Ophthalmology
year: 2015
authors: Mathew R, Bafiq R, Ramu J, Pearce E, Richardson M, Drasar E, Thein SL, Sivaprasad S
summary/abstract:AIM:
To evaluate spectral domain optical coherence tomography (SD-OCT) changes in central retina and choroid in patients with sickle cell disease (SCD).
METHODS:
Data on visual acuity, severity of sickle cell retinopathy, macular volume scans and choroidal thickness on SD-OCT were analysed from 208 eyes of 107 consecutive patients referred for screening for SCD. The retinal and choroidal thickness of eyes with SCD were also compared with age and ethnicity matched controls.
RESULTS:
44% of the eyes of patients with SCD showed discrete areas of retinal thinning in the temporal macular area. Proliferative sickle cell retinopathy was more prevalent in these eyes compared with SCD eyes with normal macular morphology (67% vs. 48%; p=0.0017). The temporal total and inner retinal thickness, macular volume and choroidal thickness were significantly lower in patients with SCD compared with age, gender and ethnicity matched controls. Macular splaying (widening of the macular contour) was noted in 30% of eyes in both groups. The choroidal and retinal thickness values showed good intergrader reliability using weighted κ statistics (0.550-0.9).
CONCLUSIONS:
Quantitative and qualitative changes on SD-OCT are present in asymptomatic SCD eyes. Proliferative retinopathy is more prevalent in eyes with discrete areas of macular thinning.
organization: King's College Hospital NHS Foundation Trust, London; King's College London; James Black Centre, London; UK NIHR Moorfields Biomedical Research CentreDOI: 10.1136/bjophthalmol-2014-305532
read more full text
+myBinderRelated Content
-
Pregnancy and Sickle Cell Disease: A Review of the Current LiteratureSickle cell disease (SCD) is the most co...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Guideline on the management of acute chest syndrome in sickle cell diseaseSickle cell disease (SCD) affects 12 000...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Sickle cell trait may not contribute to stroke riskSickle cell trait may not be an ...
-
Dr. Doris Wethers, 91, on Front Lines against Sickle Cell, DiesDr. Doris L. Wethers, who broke racial b...
-
Black Americans With Sickle Cell Trait At Increased Risk Of Kidney DiseaseAfrican Americans with sickle cell trait...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.